Table 1.
Demographic and baseline clinical characteristics of the GRACE-IgANI cohort
| Gender, male-to-female n (ratio) | 142:59 (2.4:1) |
| Age, y, mean±SD) | 36±10.02 |
| BMI, mean±SD) | 24.7±4.05 |
| Hypertension, yes/evaluable patients (%) | 169/201 (84.1) |
| Time to renal biopsy from onset of hypertension, mo, median (IQR) (n) | 10 (2–36) (167) |
| Systolic blood pressure, mm Hg (mean±SD | 138±20.33 |
| Diastolic blood pressure, mm Hg, mean±SD | 86.69±12.56 |
| Mean arterial pressure, mm Hg, mean±SD | 103.95±14.34 |
| Blood pressure ≥140/90mm Hg, yes/evaluable patients (%) | 110/201 (55%) |
| Synpharyngitic illness prior to presentation, yes/evaluable patients (%) | 8/200 (4) |
| Pedal edema prior to presentation, yes/evaluable patients (%) | 93/200 (46.5) |
| Time to renal biopsy from onset of pedal edema, mo, median (IQR) (n) | 4 (2–11.5) (93) |
| Visible hematuria prior to presentation , yes/evaluable patients (%) | 20/200 (10) |
| Time to renal biopsy from onset of visible hematuria, mo, median (IQR) (n) | 4 (2–63) (19) |
| Renal dysfunction prior to presentation, yes/evaluable patients (%) | 149/188 (79.3) |
| Time to renal biopsy from onset of renal dysfunction, mo, median (IQR) (n) | 3 (1–7) (184) |
| Proteinuria prior to presentation , yes/evaluable patients (%) | 157/160 (98.1) |
| Time to renal biopsy from onset of proteinuria, mo, median (IQR) (n) | 2 (1–8) (160) |
| Nonvisible hematuria prior to presentation , yes/evaluable patients (%) | 90/124 (72.6) |
| Time to renal biopsy from onset of nonvisible hematuria, mo, median (IQR) (n) | 2 (1–7.75) (120) |
| Family history of CKD, yes/evaluable patients (%) | 11/201 (5.5) |
| On RASB prior to biopsy, yes/evaluable patients (%) | 74/201 (37) |
| Prior exposure to immunosuppression, yes/evaluable patients (%) | 0/201 (0) |
These data were collected from the patients’ medical records prior to inclusion in the GRACE-IgANI cohort. For some patients, these data were not available.
BMI, body mass index; CKD, chronic kidney disease; GRACE-IgANI, Glomerular Research And Clinical Experiments–IgA Nephropathy in Indians; IQR, interquartile range; RASB, renin-angiotensin system blockers; SD, standard deviation.